. 2016 Feb 20;7(12):14605–14615. doi: 10.18632/oncotarget.7522

Table 1. Percentages of patient cancer samples testing positive for CCK2R expression by cancer subtype.

	Tumor Type	IHC	IHC	From Literature ^(reference) Ligand Binding	PCR
Non-neuroendocrine tumors	Astrocytomas				65%⁽⁴⁾
	Colorectal		33%⁽¹⁵⁾/39%⁽¹⁵⁾	56%⁽¹¹⁾	11%⁽¹²⁾/38%⁽⁹⁾/44%⁽⁷⁾/69%⁽⁵⁾/100%⁽⁸⁾
	Esophageal		16%⁽¹⁴⁾
	Liver (cholangiocarcinoma)		90%⁽¹⁷⁾
	Liver (fibrolamellar carcinoma)		90%⁽¹⁷⁾
	Liver (hepatocellular carcinoma)	98%	91%⁽¹⁷⁾		80%⁽⁵⁾
	Lung (non-small cell)	96%		8%⁽⁵⁾	6%⁽⁶⁾/75%⁽⁵⁾
	Ovarian				100%⁽⁴⁾
	Pancreatic	100%			57%⁽⁵⁾/100%⁽¹⁰⁾
	Stomach		56%⁽³⁷⁾	25%⁽⁵⁾	75% ⁽⁵⁾/100%⁽¹³⁾
	Thyroid (non-medullary carcinoma)	100%
Neuroendocrine / carcinoid tumors	Bronchial carcinoids			62%⁽¹⁸⁾
	Carcinoids of the bowels			30%⁽¹⁸⁾/67%⁽¹⁹⁾/88%⁽⁵⁾	100%⁽⁵⁾
	Carcinoids of the stomach		100%⁽²²⁾	95%⁽¹⁹⁾
	GIST	100%	61%⁽²⁾	100%⁽⁵⁾	57 %⁽²⁾/100%⁽⁵⁾
	Lung (non-small cell neuroendocrine tumors)	100%		50%⁽⁵⁾
	Lung (small cell)			78%⁽⁵⁾	57%⁽⁴⁾/89%⁽⁵¹/100%⁽⁶⁾
	Pancreatic neuroendocrine tumors		95%⁽¹⁶⁾	100%⁽⁵⁾/100%⁽¹⁹⁾/100%⁽¹⁸⁾	100%⁽⁵⁾
	Paraganglioma			33%⁽¹⁹⁾
	Thyroid (medullary carcinoma)	100%	60%⁽²¹⁾	92%⁽²⁰⁾	58%⁽²¹⁾/92%⁽⁴⁾

Literature reports of the expression of CCK2R as determined by immunohistochemistry (IHC), binding of radiolabeled ligands (ligand binding) or presence of mRNA (PCR/northern blot) are summarized. The percentages of samples positive for CCK2R in the literature are shown in the final three columns. The percentages of samples positive for CCK2R in our IHC studies are shown in the first column.